Pharmaceuticals News and Research

RSS

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

Driven by increasing demand for its cloud-based data insights solution, Comprehend Systems further expands its reach in the clinical research space with a partnership with Merge Healthcare's eClinical Solutions division.

21 Jun 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Accovion voted as "Rising Star" and ranked in top 10 of CROs in recent survey

Accovion GmbH, a full-service provider of clinical development services to the pharmaceutical, biotechnology and medical device industries and headquartered in Eschborn, Germany, has been voted a "Rising Star" and ranked the clinical research organisation in the top 10 of CROs in a recent survey.

20 Jun 2013

First Edition: June 20, 2013

Today's headlines include a variety of reports about the health law's implementation as well as related developments from Capitol Hill.

20 Jun 2013

Staph-killing compound may be effective against osteomyelitis

Osteomyelitis - a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria - is particularly challenging to treat.

20 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

High Court: Feds can sue pharmaceutical companies over deals to delay generic drug sales

The Supreme Court ruled Monday that the Federal Trade Commission can challenge name brand drug makers for potential antitrust violations.

19 Jun 2013

Diet, lifestyle and environment attribute to the cause of majority of cancer cases

Diet, lifestyle and the environment are all factors attributed to the cause of the majority of cancer cases and it has been estimated that up to half of all cancers may be preventable according to research by a University of Leicester scientist.

19 Jun 2013

New framework to improve safety and effectiveness of surgical procedures, implantable devices

An international team of investigators co-led by Weill Cornell Medical College is offering a new framework for evidence-based surgery and device research, similar to the kind of risk and benefit analysis used in evidence-based medicine.

19 Jun 2013

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

Both the number of patients and trial duration heavily impact a Phase 1 oncology trial's total cost. The underlying force driving most costs is patient enrollment. As the time to reach full enrollment increases, the trial lasts longer and the cost of maintaining and staffing clinical sites rises.

19 Jun 2013

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Fibromyalgia, a painful condition affecting approximately 10 million people in the U.S., is not imaginary after all, as some doctors have believed. A discovery, published this month in PAIN MEDICINE (the journal of the American Academy of Pain Medicine), clearly now demonstrates that fibromyalgia may have a rational biological basis located in the skin.

19 Jun 2013

Eylea can ease vision problems for wet AMD patients

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye.

19 Jun 2013

First Edition: June 18, 2013

Today's headlines include reports about a new publicity push in support of the health law.

18 Jun 2013

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.

18 Jun 2013

Pharmaceuticals News and Research

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Comprehend Systems collaborates with Merge eClinical to expands its clinical research space

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Accovion voted as "Rising Star" and ranked in top 10 of CROs in recent survey

First Edition: June 20, 2013

Staph-killing compound may be effective against osteomyelitis

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

High Court: Feds can sue pharmaceutical companies over deals to delay generic drug sales

Diet, lifestyle and environment attribute to the cause of majority of cancer cases

New framework to improve safety and effectiveness of surgical procedures, implantable devices

Patient enrollment and trial duration heavily impact the total cost of Phase 1 oncology trial

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Eylea can ease vision problems for wet AMD patients

First Edition: June 18, 2013

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence